Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:VSAR

Versartis (VSAR) Stock Price, News & Analysis

Versartis logo

About Versartis Stock (NASDAQ:VSAR)

Advanced Chart

Key Stats

Today's Range
$1.18
$1.30
50-Day Range
$1.19
$1.19
52-Week Range
$1.14
$2.76
Volume
349,963 shs
Average Volume
479,436 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Aravive, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX.

Receive VSAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Versartis and its competitors with MarketBeat's FREE daily newsletter.

VSAR Stock News Headlines

AI Meltdown Imminent: Dump These Stocks Now!
If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new invention… This could send many popular AI stocks crashing, including Nvidia. And it could happen starting as soon as June 1st.
See More Headlines

VSAR Stock Analysis - Frequently Asked Questions

Versartis, Inc. (NASDAQ:VSAR) issued its earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.96) by $0.69.

Based on aggregate information from My MarketBeat watchlists, some other companies that Versartis investors own include Progenics Pharmaceuticals (PGNX), ZIOPHARM Oncology (ZIOP), Bausch Health Companies (BHC), Flexion Therapeutics (FLXN), Genocea Biosciences (GNCA), Novavax (NVAX) and Protalix BioTherapeutics (PLX).

Company Calendar

Last Earnings
8/07/2018
Today
6/05/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VSAR
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:VSAR) was last updated on 6/5/2025 by MarketBeat.com Staff
From Our Partners